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The Editorial Board is pleased to announce that Cur-
rent Oncology is now included in the U.S. National
Library of Medicine’s PubMed search engine. PubMed
provides access to bibliographic information that spans
MEDLINE and OLDMEDLINE, plus out-of-scope citations
(for example, articles on plate tectonics and astrophys-
ics) from certain MEDLINE journals, primarily those on
general science and chemistry, whose life sciences
articles are indexed for MEDLINE. Until now, Current
Oncology has principally been indexed in Excerpta
Medica, and so we are pleased to record this develop-
ment and the related vote of confidence that it reflects.
“Palliative care aims to improve the life of pa-
tients and families through the early identification and
impeccable management of suffering associated with
advanced illness and emphasis on the positive aspects
of life ...” So begins the overview from Dr. Neil
MacDonald in his article discussing current and past
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cancer symptom trials and, in particular, their scope
and limitations. His hard-hitting conclusions are wor-
thy of study.
Dr. Richard Mould continues his review of sig-
nificant past events that helped shape modern radio-
therapy practices in his review of the management of
benign diseases (a favourite examination topic in years
gone by).
Drs. Goss, Richardson, and Johnston introduce our
new section titled “Canadian Centre Activities” with
a review of the National Cancer Institute of Canada
Clinical Trials Group MAP.3 trial, an international
breast cancer prevention trial.
And in the Practice Guidelines section, panel re-
views of the management of glioblastoma multiforme
and the role of alemtuzumab in chronic lymphocytic
leukemia are respectively chaired by Dr. Warren
Mason and Dr. Christopher Smith.